Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Pipeline Analysis 2017 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Pipeline Analysis 2017

  • ID: 4340322
  • Report
  • 151 pages
  • P&S Market Research
1 of 3
Disease Overview

Chronic obstructive pulmonary disease (COPD) is a broad term used for progression of various diseases affecting the lungs such as, chronic bronchitis, some forms of bronchiectasis, emphysema and refractory (non-reversible) asthma. Breathlessness and coughing are few of the early symptoms that induce the hypothesis of having COPD, but some people also consider these symptoms as the signs of aging. In no time, these ailments come under severe progression and reveal the rising of other associated diseases. The primary diagnosis of COPD is spirometry, which is the most common form of pulmonary function test that includes measurement of volume and flow of inhaled and exhaled air in the lungs. Therefore, analyzing the breathing pattern may assess the complications involved with the lungs. COPD is a disease that develops over the years and the associated symptoms are wheezing, tightness in chest, increased breathlessness and frequent coughing.

In COPD, the lungs cells lose their quality of elasticity, most of the air sacs are destroyed, and the walls of the airways become thick and inflamed and in some cases also become clogged by mucus. Chronic bronchitis and emphysema are the two-main conditions that progress throughout the period of progression of the disease, due to which air sacs lose their shape and become floppy. The destruction of walls of air sacs leads to the enlargement of these sacs, and they no longer remain in their normal shape, which further leads to reduction in the amount of gas exchange in the lungs. According to the data provided by National Institutes of Health (NIH), nearly 12 million adults in the U.S. are suffering from COPD, of which 120,000 people die every year. Therefore, various combination therapies and advanced technologies are driving the growth of chronic obstructive pulmonary disease pipeline. Also, drug manufacturing companies are using various promising targets for the treatment of the disease. Targeted therapy is more effective in achieving good results. The potential targets will possibly stop or slow the progression of the disease with better efficacy and lesser side effects.

Pipeline Analysis

As of May 2017, the COPD therapeutics pipeline comprises approximately 65 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for the treatment of COPD include Chiesi Farmaceutici S.p.A., AstraZeneca plc, GlaxoSmithKline plc and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
  • Market Forecast - Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Chronic Obstructive Pulmonary Disease Pipeline Analysis
4.4.1 Pipeline Analysis By Phase
4.4.2 Pipeline Analysis By Molecule Type
4.4.3 Pipeline Analysis By Route Of Administration
4.4.4 Pipeline Analysis By Company

5. Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis By Phase (2017)
5.1 Phase Iii: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Ii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Pre-Clinical: Drug Candidates
5.4 Discovery: Drug Candidates

6 Competitive Landscape
6.1 Key Players Benchmarking For Chronic Obstructive Pulmonary Disease Drug Candidates
6.2 Swot Analysis Of Chronic Obstructive Pulmonary Disease Therapeutics Pipeline

7 Company Profiles
7.1 Business Overview
7.2 Product And Service Offerings

8 Appendix
8.1 Abbreviations

List Of Tables
Pipeline Analysis Of Chronic Obstructive Pulmonary Disease, By Company (2017)
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Pre-Clinical Drug Candidates
Discovery Drug Candidates
Companies- At A Glance

List Of Figures
Research Methodology For Chronic Obstructive Pulmonary Disease Pipeline Analysis
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Number Of Chronic Obstructive Pulmonary Diseasedrug Candidates Under Development (2017)
Chronic Obstructive Pulmonary Disease Pipeline Split, By Molecule Type (2017)
Chronic Obstructive Pulmonary Disease Pipeline Split, By Route Of Administration (2017)
Key Players Benchmarking For Chronic Obstructive Pulmonary Disease Drug Candidates
Swot Analysis Of Chronic Obstructive Pulmonary Disease Therapeutics Pipeline
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll